MICROPORT (00853) saw its stock price surge 5.95% in early trading on Monday, following the publication of groundbreaking clinical trial results for its Firehawk® Drug Eluting Stent System. The study, published in the prestigious New England Journal of Medicine and presented at the European Society of Cardiology Congress 2025, demonstrates a significant advancement in the treatment of low-risk acute myocardial infarction patients.

The TARGET-FIRST clinical trial results show that patients treated with MicroPort's Firehawk® stents can reduce their dual antiplatelet therapy from the standard 12 months to just one month. This shortened treatment duration does not increase ischemic risks and leads to a remarkable 54% decrease in bleeding complications. The study's publication in such a high-impact journal and its presentation at a leading cardiovascular conference underscores the significance of this medical breakthrough.

Investors appear to be reacting positively to the potential market implications of these findings. The Firehawk® stent, which has already been introduced in 67 countries across multiple continents, may now see increased adoption and sales, particularly as the company focuses on commercialization in the North American market. This development could significantly strengthen MicroPort's position in the global cardiovascular medical device market, potentially leading to increased revenue and market share in the coming years.